KR20020097236A - 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험 - Google Patents

타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험 Download PDF

Info

Publication number
KR20020097236A
KR20020097236A KR1020027014447A KR20027014447A KR20020097236A KR 20020097236 A KR20020097236 A KR 20020097236A KR 1020027014447 A KR1020027014447 A KR 1020027014447A KR 20027014447 A KR20027014447 A KR 20027014447A KR 20020097236 A KR20020097236 A KR 20020097236A
Authority
KR
South Korea
Prior art keywords
gip
type
diabetes
subject
ifg
Prior art date
Application number
KR1020027014447A
Other languages
English (en)
Korean (ko)
Inventor
마이클 에이. 나욱크
주리스 제이. 마이에르
카트린 후엑킹
Original Assignee
바이오네브라스카, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오네브라스카, 인코포레이티드 filed Critical 바이오네브라스카, 인코포레이티드
Publication of KR20020097236A publication Critical patent/KR20020097236A/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
KR1020027014447A 2000-04-27 2001-04-26 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험 KR20020097236A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55977900A 2000-04-27 2000-04-27
US09/559,779 2000-04-27
PCT/US2001/013378 WO2001081919A2 (fr) 2000-04-27 2001-04-26 Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun

Publications (1)

Publication Number Publication Date
KR20020097236A true KR20020097236A (ko) 2002-12-31

Family

ID=24234987

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027014447A KR20020097236A (ko) 2000-04-27 2001-04-26 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험

Country Status (5)

Country Link
EP (1) EP1356295A2 (fr)
KR (1) KR20020097236A (fr)
AU (1) AU2001257278A1 (fr)
CA (1) CA2405900A1 (fr)
WO (1) WO2001081919A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
JP2008530130A (ja) * 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2628241C (fr) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
JP2009537812A (ja) * 2006-05-15 2009-10-29 デジラブ インコーポレーテッド ２型糖尿病プリフォームのバイオマーカー、及び２型糖尿病プリフォームの存在又は不在を検出する方法
EP1857818A1 (fr) * 2006-05-15 2007-11-21 DIGILAB BioVisioN GmbH Diagnostic et usages thérapeutiques des peptides pour les formes de diabète précoces de type 2 et les conditions correspondantes
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2702289A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
MX2010004297A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Antagonistas de glucagon.
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN104945500B (zh) 2008-06-17 2019-07-09 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
JP2012512903A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
RU2012101274A (ru) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
WO2011094337A1 (fr) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
EP2569000B1 (fr) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
PE20140724A1 (es) 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp Coagonistas del receptor de glucagon/glp-1
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
WO2013192129A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
CN108627651A (zh) * 2013-09-20 2018-10-09 阿斯图特医药公司 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
US10317359B2 (en) 2016-01-05 2019-06-11 Ravi Kumar Meruva Differential carbon dioxide sensor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04145099A (ja) * 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途

Also Published As

Publication number Publication date
EP1356295A2 (fr) 2003-10-29
WO2001081919A2 (fr) 2001-11-01
AU2001257278A1 (en) 2001-11-07
CA2405900A1 (fr) 2001-11-01
WO2001081919A3 (fr) 2003-04-24

Similar Documents

Publication Publication Date Title
KR20020097236A (ko) 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험
Nanjo et al. Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin.
EP1928499B1 (fr) Utilisation d un inhibiteur de la ddp-iv en vue de réduire les crises d hypoglycémie
Ryder et al. Use of a novel impermeable biotinylated photolabeling reagent to assess insulin-and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients.
Frystyk Free insulin-like growth factors–measurements and relationships to growth hormone secretion and glucose homeostasis
Faber et al. Kinetics of human connecting peptide in normal and diabetic subjects.
Meier et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes
Yabe et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients
US8008024B2 (en) Methods, products and treatments for diabetes
Vuorinen-Markkola et al. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non—insulin-dependent diabetes mellitus
CN1942767A (zh) 对2型糖尿病、葡萄糖耐量低减、空腹血糖异常的易感性测定的肠抑胃肽判断试验
CZ69596A3 (en) Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
IL120081A (en) Methods for determining trait-related properties of amylin agonists and antagonists
AU5489400A (en) Glp-1 as a diagnostic test to determine beta-cell function and the presence of the condition of igt and type-ii diabetes
RUBENSTEIN et al. Clinical significance of circulating proinsulin and C-peptide
Knop et al. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance
JP2024037767A (ja) 改変型線維芽細胞成長因子２１（ｆｇｆ－２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法
Meier et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects
Pietrobelli et al. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values
Pagano et al. Insulin resistance in the aged: a quantitative evaluation of in vivo insulin sensitivity and in vitro glucose transport
Crowne et al. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus
Ilag et al. Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4alpha/MODY1 gene.
Veedfald et al. Entero-pancreatic hormone secretion, gastric emptying, and glucose absorption after frequently sampled meal tests
D'Alessio et al. Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men
US20240041986A1 (en) Methods and compositions for the treatment and prevention of type 1 diabetes

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application